title: Renal Artery Stenosis: Optimal Therapy and Indications for Revascularization.
abstract: Atherosclerotic renal artery stenosis (ARAS) is associated with increased cardiovascular risk and overall mortality. Manifestations of ARAS include resistant or malignant hypertension, progressive deterioration of renal function, and cardiac dysfunction syndromes of flash pulmonary edema and angina. Diagnosis rests upon non-invasive studies such as duplex ultrasonography and is confirmed using invasive renal arteriography. Regardless of the severity of ARAS, management of this entity has been a topic of contentious debate. For over two decades, the use of percutaneous revascularization to treat ARAS has been studied with various clinical trials. Though case series seem to demonstrate favorable clinical response to revascularization, the overwhelming majority of randomized clinical trials have not mirrored a robust outcome. In these trials, poor correlation is noted between the reduction of stenosis and the improvement of renovascular hypertension and glomerular filtration rate, and decrease in cardiovascular outcomes and mortality. With dichotomizing results, the explanation for these discrepant findings has been attributed to improper trial design and inappropriate patient selection. An overview of the treatment options available will be provided, with a focus on the methodology and design of clinical trials investigating the efficacy of percutaneous revascularization. Emphasis is placed on appropriate patient selection criteria, which may necessitate the use of hemodynamic lesion assessment and clinical correlation based on individualized care. When clinical equipoise exists between optimal medical therapy and revascularization, the current paradigm supports ongoing medical therapy as the treatment of choice. However, renal artery stenting remains a viable therapeutic option for those who continue to have clinical syndromes consistent with renal hypoperfusion while adequately treated with optimal medical therapy. Despite observational studies suggesting clinical benefit for this specific patient population, there remains a paucity of randomized clinical trial data. Further trials targeting the patients who are inadequately treated with optimal medical therapy need to be undertaken to confirm the efficacy of revascularization.
authors.affiliation: Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
authors.forename: Sandeep M
authors.initials: SM
authors.lastname: Patel
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Sahil A
authors.initials: SA
authors.lastname: Parikh
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D006978:Hypertension, Renovascular / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D018579:Patient Selection; D011379:Prognosis; D012077:Renal Artery / Q000503:physiopathology*; D012078:Renal Artery Obstruction / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D015607:Stents
chemical_list: D000959:Antihypertensive Agents